CooperVision Shares Interim Results for Myopia Control Contact Lens Clinical Trial, Raises $164,000 for Optometry Giving Sight

 CooperVision Shares Interim Results for Myopia Control Contact Lens Clinical Trial, Raises $164,000 for Optometry Giving Sight

CooperVision recently shared two-year interim results from a clinical trial assessing the specially-designed, MiSight® dual-focus myopia control 1-day soft contact lens in reducing the rate of progression of juvenile-onset myopia during the 95th annual meeting of the American Academy of Optometry (AAO) last month.

The study reportedly enrolled 144 myopic children ages 8 to 12 years old from Singapore, Canada, England, and Portugal, with three-year data anticipated in 2017. The findings indicated the use of the dual-focus contact lens, which has alternating visual correction and treatment zones, was effective in slowing myopia progression — 59 percent as measured by mean cycloplegic spherical equivalent (SE), and 53 percent as measured by mean axial elongation of the eye when compared to the children in the control group wearing a single vision 1-day contact lens.

The indication for myopia control has reportedly not been approved in the United States.

Click here to read the full press release.

And CooperVision employees helped the company provide a $164,000 donation to Optometry Giving Sight in support of the 2016 World Sight Day Challenge.

This was reportedly the fifth year employees participated by organizing various fundraisers over multiple weeks, with The Cooper Companies matching funds. More than 30 CooperVision teams and locations generated money through activities including food festivals, a mountain climbing challenge, guide dog seminars, a 5K walk/run, auctions, cupcake sales and bracelet sales.

The amount raised is reportedly the equivalent of providing 32,000 eye exams to those in need.

Click here to read the full press release.

Image courtesy CooperVision

Source: CooperVision

  • <<
  • >>

Comments